Cenicriviroc mesylate
- Generic Name
- Cenicriviroc mesylate
A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Phase 1
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Drug: TBR-652 Matching PlaceboDrug: TBR-652 50 mgDrug: TBR-652 75 mgDrug: TBR-652 100 mgDrug: TBR-652 150 mg
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01092104
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath